RxDoctor Payments Data

Mehmoodur Rasheed, MD

Rheumatology · Champaign, ILNPI 1215978473

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 54 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$468
  • AbbVie$428
  • Amgen$189
  • Janssen Scientific Affairs, LLC$98
  • Johnson & Johnson$60
  • AstraZeneca$56
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$1,32098%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 50th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$287,556
Medicare patients
342
Services billed
15,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept83$673,654
RinvoqUpadacitinib80$595,537
Humira(Cf) PenAdalimumab46$438,160
Enbrel MiniEtanercept58$427,792
Orencia ClickjectAbatacept31$221,744
Amjevita(Cf)Adalimumab-Atto13$174,408
KevzaraSarilumab36$157,390
SimponiGolimumab17$103,506
Actemra ActpenTocilizumab28$81,654
OrenciaAbatacept13$79,642
OtezlaApremilast11$54,458
ActemraTocilizumab18$46,058
Hydroxychloroquine Sulfate300$13,977
MethotrexateMethotrexate Sodium410$12,606
Leflunomide122$6,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$428$595,53780 claims
AmgenAmjevita(Cf), Otezla$189$228,86624 claims
Johnson & JohnsonSimponi$60$103,50617 claims
E.r. Squibb & Sons, L.L.C.Orencia$30$79,64213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →